Trial reportFrontiers in immunology2020
Elevated Circulating IL-10 Producing Breg, but Not Regulatory B Cell Levels, Restrain Antibody-Mediated Rejection After Kidney Transplantation.
Trial report in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06112951 (The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation: a Prospective RCT
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Early Post-Transplant Peripheral B-Cell Profiles in Kidney Transplant Recipients: Clinical Associations and Limitations.Journal of clinical medicine · 2026Article
- Influence and Role of Regulatory B Cells in Organ Transplantation: The State of the Art, Prospects, and Emerging Insights.Antibodies (Basel, Switzerland) · 2025Review
- PBK as a novel biomarker performed excellent diagnostic and prognostic value in HCC associated with immune infiltration and methylation.Journal of molecular histology · 2025Article
- Revealing the role of regulatory b cells in cancer: development, function and treatment significance.Cancer immunology, immunotherapy : CII · 2025Review
- Regulatory B cells, the key regulator to induce immune tolerance in organ transplantation.Frontiers in immunology · 2025Review
- Molecular screening of transitional B cells as a prognostic marker of improved graft outcome and reduced rejection risk in kidney transplant.Frontiers in immunology · 2024Article
- HLA class II antibody activation of endothelial cells induces M2 macrophage differentiation in peripheral blood.Clinical and experimental nephrology · 2023Article
- A bibliometric and knowledge-map analysis of antibody-mediated rejection in kidney transplantation.Renal failure · 2023Article
- Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.Frontiers in immunology · 2023Review
- Adenovirus-IL-10 relieves chronic rejection after mouse heart transplantation by inhibiting miR-155 and activating SOCS5.International journal of medical sciences · 2023Article
- Chloroquine Suppresses Effector B-Cell Functions and Has Differential Impact on Regulatory B-Cell Subsets.Frontiers in immunology · 2022Article
- Deconvolution of B cell receptor repertoire in multiple sclerosis patients revealed a delay in tBreg maturation.Frontiers in immunology · 2022Article
- Relationship of transitional regulatory B and regulatory T cells and immunosuppressive drug doses in stable renal transplant recipients.Immunity, inflammation and disease · 2021Article
- Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.Frontiers in immunology · 2021Review
- The Role of Regulatory B cells in Kidney Diseases.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-mediated rejection (AMR) occupies a major position for chronic rejection after kidney transplantation. Regulatory B cell (Breg) has been reported to have an inhibitory immune function, which contributes to the resistance for AMR. Methods: A nested case-control study for nine healthy donors, 25 stable (ST) patients, and 18 AMR patients was performed to determine the type of Breg in maintaining immune tolerance and preventing AMR. Results: Compared to the ST group, circulating interleukin (IL)-10 Conclusion: The circulating IL-10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.